Creative Med Technology Hldgs Financials
This page shows Creative Med Technology Hldgs (CELZ) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Creative Medical Technology still operates as a development-stage company, with ongoing cash burn sustained mainly by new equity funding.
Operating cash flow of-$5.9M was close to the FY2025 net loss of-$6.0M , so the reported loss largely reflects cash leaving the business rather than noncash accounting noise. That matters because cash still rose only through financing, while shares outstanding increased111.4% from FY2024, revealing a shareholder-funded runway rather than an internally financed model.
FY2025 revenue was only
With total liabilities of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Creative Med Technology Hldgs's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Creative Med Technology Hldgs has an operating margin of -102380.2%, meaning the company retains $-102380 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -52216.9% the prior year.
Creative Med Technology Hldgs's revenue declined 45.5% year-over-year, from $11K to $6K. This contraction results in a growth score of 3/100.
Creative Med Technology Hldgs carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 25.97, Creative Med Technology Hldgs holds $25.97 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
Creative Med Technology Hldgs generates a -79.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -86.6% the prior year.
Creative Med Technology Hldgs passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Creative Med Technology Hldgs generates $0.98 in operating cash flow (-$5.9M OCF vs -$6.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Creative Med Technology Hldgs generated $6K in revenue in fiscal year 2025. This represents a decrease of 45.5% from the prior year.
Creative Med Technology Hldgs reported -$6.0M in net income in fiscal year 2025. This represents a decrease of 9.1% from the prior year.
Creative Med Technology Hldgs earned $-2.52 per diluted share (EPS) in fiscal year 2025. This represents an increase of 32.1% from the prior year.
Cash & Balance Sheet
Creative Med Technology Hldgs held $7.2M in cash against $0 in long-term debt as of fiscal year 2025.
Creative Med Technology Hldgs had 4M shares outstanding in fiscal year 2025. This represents an increase of 111.4% from the prior year.
Margins & Returns
Creative Med Technology Hldgs's gross margin was 63.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.4 percentage points from the prior year.
Creative Med Technology Hldgs's operating margin was -102380.2% in fiscal year 2025, reflecting core business profitability. This is down 50163.3 percentage points from the prior year.
Creative Med Technology Hldgs's net profit margin was -99916.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 49976.1 percentage points from the prior year.
Creative Med Technology Hldgs's ROE was -79.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 6.9 percentage points from the prior year.
Capital Allocation
Creative Med Technology Hldgs invested $2.3M in research and development in fiscal year 2025. This represents a decrease of 5.9% from the prior year.
Creative Med Technology Hldgs spent $10K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 94.3% from the prior year.
CELZ Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $0 | $0-100.0% | $3K | N/A | $0-100.0% | $8K |
| Cost of Revenue | $0 | N/A | $0 | $0-100.0% | $1K | N/A | $0-100.0% | $3K |
| Gross Profit | $0 | N/A | $0 | $0-100.0% | $2K | N/A | $0-100.0% | $5K |
| R&D Expenses | $542K | N/A | $465K-7.2% | $501K-32.6% | $743K | N/A | $582K-37.1% | $925K |
| SG&A Expenses | $889K | N/A | $777K+6.2% | $732K-17.7% | $888K | N/A | $499K-26.3% | $676K |
| Operating Income | -$1.5M | N/A | -$1.3M-0.8% | -$1.3M+23.9% | -$1.7M | N/A | -$1.1M+31.7% | -$1.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | N/A | $0 | $0 | $0 | N/A | $0 | $0 |
| Net Income | -$1.4M | N/A | -$1.2M-0.2% | -$1.2M+24.7% | -$1.6M | N/A | -$1.0M+33.2% | -$1.6M |
| EPS (Diluted) | $-0.38 | N/A | $-0.480.0% | $-0.48+42.2% | $-0.83 | N/A | $-0.75+32.4% | $-1.11 |
CELZ Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.4M-17.5% | $7.8M+33.4% | $5.9M-17.6% | $7.1M-14.9% | $8.3M+25.2% | $6.7M-3.2% | $6.9M-13.8% | $8.0M |
| Current Assets | $6.1M-18.1% | $7.4M+36.7% | $5.4M-18.4% | $6.6M-15.4% | $7.8M+27.9% | $6.1M-3.1% | $6.3M-16.7% | $7.6M |
| Cash & Equivalents | $5.7M-20.6% | $7.2M+34.1% | $5.4M-17.9% | $6.5M-15.0% | $7.7M+29.7% | $5.9M-5.1% | $6.3M-16.2% | $7.5M |
| Inventory | $125K | $0-100.0% | $9940.0% | $9940.0% | $994-54.7% | $2K-35.4% | $3K0.0% | $3K |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $308K+8.0% | $285K+9.0% | $261K-5.9% | $278K-3.1% | $286K-12.6% | $328K-1.0% | $331K-12.1% | $376K |
| Current Liabilities | $308K+8.0% | $285K+9.0% | $261K-5.9% | $278K-3.1% | $286K-12.6% | $328K-1.0% | $331K-12.1% | $376K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $6.1M-18.7% | $7.5M+34.4% | $5.6M-18.1% | $6.8M-15.3% | $8.1M+27.1% | $6.3M-3.3% | $6.6M-13.9% | $7.6M |
| Retained Earnings | -$72.0M-2.0% | -$70.6M-2.7% | -$68.7M-1.8% | -$67.5M-1.9% | -$66.2M-2.5% | -$64.6M-3.0% | -$62.7M-1.7% | -$61.7M |
CELZ Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.3M+31.7% | -$1.9M-65.8% | -$1.2M-0.9% | -$1.2M+27.2% | -$1.6M+18.4% | -$1.9M-97.8% | -$986K+32.9% | -$1.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | -$175K-246.5% | -$51K | $0 | $0 | $0 | $0+100.0% | -$200K | $0 |
| Financing Cash Flow | $13K-99.7% | $3.8M | $0 | $0-100.0% | $3.4M+105.8% | $1.6M+6502.8% | -$25K+61.8% | -$67K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | $0 | $0 | $0 | $0-100.0% | $10K | $0-100.0% | $25K-61.9% | $67K |
CELZ Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.0% | N/A | N/A | N/A | 60.0% | N/A | N/A | 60.0% |
| Operating Margin | -48638.4% | N/A | N/A | N/A | -55349.3% | N/A | N/A | -20316.3% |
| Net Margin | -46835.9% | N/A | N/A | N/A | -54603.2% | N/A | N/A | -19471.6% |
| Return on Equity | -23.0% | N/A | -22.1%-4.0pp | -18.1%+2.3pp | -20.3% | N/A | -15.9%+4.6pp | -20.5% |
| Return on Assets | -21.8% | N/A | -21.1%-3.8pp | -17.4%+2.3pp | -19.6% | N/A | -15.1%+4.4pp | -19.5% |
| Current Ratio | 19.69-6.3 | 25.97+5.3 | 20.71-3.2 | 23.89-3.5 | 27.39+8.7 | 18.73-0.4 | 19.13-1.1 | 20.21 |
| Debt-to-Equity | 0.05+0.0 | 0.040.0 | 0.050.0 | 0.040.0 | 0.04-0.0 | 0.050.0 | 0.050.0 | 0.05 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Creative Med Technology Hldgs's annual revenue?
Creative Med Technology Hldgs (CELZ) reported $6K in total revenue for fiscal year 2025. This represents a -45.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Creative Med Technology Hldgs's revenue growing?
Creative Med Technology Hldgs (CELZ) revenue declined by 45.5% year-over-year, from $11K to $6K in fiscal year 2025.
Is Creative Med Technology Hldgs profitable?
No, Creative Med Technology Hldgs (CELZ) reported a net income of -$6.0M in fiscal year 2025, with a net profit margin of -99916.8%.
What is Creative Med Technology Hldgs's gross margin?
Creative Med Technology Hldgs (CELZ) had a gross margin of 63.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Creative Med Technology Hldgs's operating margin?
Creative Med Technology Hldgs (CELZ) had an operating margin of -102380.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Creative Med Technology Hldgs's net profit margin?
Creative Med Technology Hldgs (CELZ) had a net profit margin of -99916.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Creative Med Technology Hldgs's return on equity (ROE)?
Creative Med Technology Hldgs (CELZ) has a return on equity of -79.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Creative Med Technology Hldgs's operating cash flow?
Creative Med Technology Hldgs (CELZ) generated -$5.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Creative Med Technology Hldgs's total assets?
Creative Med Technology Hldgs (CELZ) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Creative Med Technology Hldgs spend on research and development?
Creative Med Technology Hldgs (CELZ) invested $2.3M in research and development during fiscal year 2025.
What is Creative Med Technology Hldgs's current ratio?
Creative Med Technology Hldgs (CELZ) had a current ratio of 25.97 as of fiscal year 2025, which is generally considered healthy.
What is Creative Med Technology Hldgs's debt-to-equity ratio?
Creative Med Technology Hldgs (CELZ) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Creative Med Technology Hldgs's return on assets (ROA)?
Creative Med Technology Hldgs (CELZ) had a return on assets of -76.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Creative Med Technology Hldgs's cash runway?
Based on fiscal year 2025 data, Creative Med Technology Hldgs (CELZ) had $7.2M in cash against an annual operating cash burn of $5.9M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Creative Med Technology Hldgs's Piotroski F-Score?
Creative Med Technology Hldgs (CELZ) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Creative Med Technology Hldgs's earnings high quality?
Creative Med Technology Hldgs (CELZ) has an earnings quality ratio of 0.98x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Creative Med Technology Hldgs?
Creative Med Technology Hldgs (CELZ) scores 34 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.